An established patient, a 72-year-old male with a 6-year history of Parkinson disease, pre… — USMLE Step 3

An established patient, a 72-year-old male with a 6-year history of Parkinson disease, presents to the outpatient neurology clinic accompanied by his wife. Over the past three weeks, he has experienced new-onset visual hallucinations, frequently reporting that strangers are standing in their living room. These episodes cause him significant distress. His motor symptoms remain well-controlled. His current daily medication regimen consists of carbidopa-levodopa, pramipexole, selegiline, and trihexyphenidyl. He takes no other medications. Vital signs include a temperature of $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure of $134/76\text{ mmHg}$ , pulse of $72\text{/min}$ , and respiratory rate of $16\text{/min}$ . Physical examination is remarkable for a mild resting pill-rolling tremor and slight bradykinesia, unchanged from previous visits. Laboratory results, including a complete blood count, comprehensive metabolic panel, and urinalysis, show no abnormalities.

Arrange the following pharmacologic interventions in the chronological sequence they should be implemented (from first step to last step) to appropriately manage this patient's new-onset psychosis.

1Discontinue trihexyphenidyl
2Discontinue selegiline
3Discontinue pramipexole
4Initiate low-dose quetiapine

Answer

The correct sequence for managing Parkinson disease psychosis is to sequentially discontinue adjunctive medications starting with the highest risk/lowest benefit agents (trihexyphenidyl, then selegiline, then pramipexole), followed by initiating a low-risk atypical antipsychotic (quetiapine) only if symptoms persist.

The management of medication-induced psychosis in Parkinson disease follows a strict, stepwise protocol to balance the alleviation of psychiatric symptoms with the preservation of motor function. After ruling out infectious or metabolic causes of delirium, clinicians must sequentially withdraw adjunctive Parkinson medications based on their risk-to-benefit profile. Anticholinergics (e.g., trihexyphenidyl) are stopped first because they carry the highest risk of hallucinosis and confusion, particularly in older adults, while offering the least benefit for bradykinesia. If symptoms persist, MAO-B inhibitors (e.g., selegiline) and amantadine are stopped next. If further intervention is required, dopamine agonists (e.g., pramipexole) are tapered and discontinued. Carbidopa-levodopa is maintained as long as possible due to its superior efficacy in controlling motor symptoms. Only after these adjunctive agents have been sequentially withdrawn should a low-risk atypical antipsychotic (such as quetiapine, pimavanserin, or clozapine) be initiated.

Step-by-Step Solution

Evaluate for and rule out secondary causes of altered mental status.

Normal vital signs and laboratory findings (including urinalysis) rule out underlying infections, metabolic derangements, or other etiologies of delirium.

Before adjusting Parkinson disease medications, acute medical illnesses that precipitate delirium must be excluded.

Identify the adjunctive Parkinson disease medication with the highest neuropsychiatric risk and lowest motor benefit.

Trihexyphenidyl is identified as the primary target for discontinuation.

Anticholinergics are highly associated with confusion and visual hallucinations in older adults and should be the first medications tapered and stopped.

Determine the subsequent order of medication withdrawal if psychosis does not resolve.

Selegiline is discontinued next, followed by pramipexole.

The standard step-wise de-escalation algorithm prioritizes removing MAO-B inhibitors (selegiline) followed by dopamine agonists (pramipexole), while attempting to maintain carbidopa-levodopa to preserve motor function.

Select the appropriate pharmacologic addition if symptoms remain refractory to de-escalation.

Initiate a low-potency atypical antipsychotic, such as quetiapine.

Adding an antipsychotic is reserved as the final step to minimize polypharmacy. Quetiapine, pimavanserin, or clozapine are preferred as they do not significantly worsen extrapyramidal motor symptoms.

Key Concept

Management of Parkinson disease psychosis requires ruling out secondary causes of delirium, followed by a stepwise withdrawal of adjunctive medications (anticholinergics -> amantadine/MAO-B inhibitors -> dopamine agonists), before finally considering the addition of a specialized atypical antipsychotic.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic